Aurora Cannabis Achieves Plant Breeders’ Rights to Enhance Cannabis Genetics Leadership

Aurora Cannabis Secures Plant Breeders' Rights for Cannabis Cultivars

In a significant advancement for the cannabis sector, Aurora Cannabis Inc., a prominent player in the medical cannabis industry, has officially been granted Plant Breeders' Rights (PBR) in Canada for two of its proprietary cannabis varieties. This achievement acknowledges the extensive research and development efforts behind these cultivars, bolstering Aurora's leadership position in cannabis science.

The Newly Granted Genetics

The cultivars that have gained protection are Farm Gas™ (SOT20R07-007) and Driftwood Diesel™ (SOT20R07-005). Both of these varieties were developed at Aurora Coast, the company’s premier research facility located in Comox, British Columbia. The decision to protect these specific genetics stems from their distinct growing characteristics and reliable performance, which are crucial for producing consistent medical cannabis products. Currently, Farm Gas™ and Driftwood Diesel™ are available to patients in several countries, including Germany, Poland, the United Kingdom, Canada, and Australia.

Lana Culley, Aurora's Vice President of Innovation and International Operations, emphasized that the awarded Plant Breeders' Rights reflect the deep scientific commitment behind these cultivars. She stated, "These rights represent the disciplined, science-driven approach we've employed to develop varieties that ensure consistency and reliability in performance for our medical cannabis patients around the globe."

Understanding Plant Breeders' Rights

Plant Breeders' Rights are a form of intellectual property protection afforded to new and distinct plant varieties, akin to patents but specific to horticultural innovations. In Canada, these rights are administered by the Canadian Food Inspection Agency (CFIA). They grant breeders the exclusive authority to produce, propagate, and sell the protected plant varieties, acknowledging the significant scientific investment needed to innovate and maintain distinct plant characteristics over time.

For Aurora, securing Plant Breeders' Rights not only safeguards its proprietary cannabis genetics developed through an extensive breeding program but also supports ongoing innovation and long-term research endeavors. This robust genetics platform underpins the company's status as a global leader in the medical cannabis market, paving the way for developing differentiated premium products characterized by high reliability and quality.

Moreover, the recent PBR not only strengthens Aurora's position domestically but also enhances its competitive standing on the global stage, especially in light of its recent efforts towards securing similar protections for select varieties in Europe. This strategic move significantly amplifies the company's ability to attract a wider market share and reinforces its overarching goals.

The Vision of Aurora Cannabis

As a company, Aurora Cannabis is dedicated to improving the quality of life through superior scientific expertise and a commitment to patient-centric care. Its operational footprint spans multiple continents, targeting both medical and consumer markets. Aurora's strategic focus on high-margin opportunities, combined with their reliable and innovative product offerings, positions the company for growth in an evolving landscape.

With a comprehensive portfolio featuring renowned brands like Aurora®, MedReleaf®, and Whistler Medical Marijuana Co.®, Aurora continues to push the envelope in the cannabis space. Its state-of-the-art manufacturing facilities in Canada and Germany ensure that high-quality cannabis products are consistently delivered to meet patient needs.

For more information about Aurora's initiatives and to follow their journey in the cannabis industry, visit their official website at www.auroramj.com. Their common shares are traded on NASDAQ and TSX under the symbol 'ACB'.

In summary, the granting of Plant Breeders' Rights marks a pivotal moment for Aurora Cannabis, reaffirming its commitment to scientific innovation, quality assurance, and meeting the diverse needs of patients worldwide. With these new rights in hand, Aurora is well-positioned to lead the future of medical cannabis.